«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2020年04期

页码:

540-543

栏目:

综述

出版日期:

2020-08-20

文章信息/Info

Title:

-

作者:

胡 蓉¹ 李 涛¹ 周林福¹; 2

210029 南京,南京医科大学第一附属医院呼吸与危重症医学科¹ 210029 南京,南京医科大学中西医结合研究所²

Author(s):

-

关键词:

阿帕替尼;  支气管肺癌;  血管生成;  血管内皮生长因子受体-2;  临床试验

Keywords:

-

分类号:

R734

DOI:

10.3877/cma.j.issn.1674-6902.2020.04.028

摘要:

-

Abstract:

-

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin 2016, 66(2): 115-132.
3 Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
4 Tian S, Quan H, Xie C, et al. YN968D1 is novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci, 2011, 102(7): 1374-1380.
5 Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10: 529.
6 Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
7 Al-abd AM, Alamoudi AJ, Abdel-naim AB, et al. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies-A review[J]. J Adv Res, 2017, 8(6): 591-605.
8 Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition[J]. Cell Signal, 2007, 19(10): 2003-2012.
9 Hichlin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005, 23(5): 1011-1027.
10 Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-neuropilin-1 signaling promotes glionia stem-like cell viability and tumor growth[J]. J Exp Med, 2012, 209(3): 507-520.
11 Claesson-welsh L, Welsh M. VEGFA and tumour angiogenesis[J]. J Intern Med, 2013, 273(2): 114-127.
12 Luo RH, Li BQ. Clinical effect of apatinib combined with chemotherapy on patients with advanced non-small cell lung cancer after failure of first-line treatment[J]. Oncology progress, 2019, 17(15): 1809-1812.
13 Liu Z, Ou W, Li N, et al. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy[J]. Thorac Cancer, 2018, 9(10): 1285-1290.
14 Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2017, 10: 1821-1825.
15 Zhou CC. A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advenced non-squamous non-small cell lung cancer(NSCLC)patients. Presented at ASCO2018(suppl; abstr e21017).
16 Wu YL. A phase Ⅱ umbrella study of camrelizumab in different PD-L1 expression cohorts in pre-treated advenced/metastatic non-small cell lung cancer. Presented at WCLC 2019(JCSE01.09).
17 Zhang ZH, Luo F, Zhang Y, et al. Study of apatinib plus gefitinib as first-line therapy in patients with EGFR mutent advenced non-small cell lung cancer[J]. Cancer Commun(Lond), 2019, 39(1): 69.
18 Song X, Tian R, Guo Y, et al. Clinical efficacy and safety of apatinib combined with EGFR-TKIS in advanced non-small cell lung cancer with EGFR-TKIS resistance[J]. J Thorac Oncol, 2018, 13(10): 590.
19 Chen MD, Song J, Liu W. Low dose apatinib combined with EGFR-TKI in treating advanved NSCLC after first-generation EGFR-TKIS treatment failure. Presented at WCLC 2018(P3.01-16).
20 Li F, Zhu TJ, Wang JD, et al. Apatinib to enhance antitumor activity of gefitinib in non-small cell lung cancer[J]. Eur J Cancer, 2017, 84: 184-192.
21 Xu JP, Liu XY, Yang S, et al. A retrospective analysis of apatinib in advanced non-small cell lung cancer patients refractory to chemotherapy[J]. J Clil Oncol, 2015(15_suppl): e20562-e20562.
22 Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J]. Eur J Cancer, 2017, 84: 184-192.
23 Poindessous V, Ouaret D, Ei Ouadrani K, et al. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies[J]. Clin Cancer Res, 2011, 17(20): 6522-6530.
24 Lv T, Song Y, Liu H, et al. A pilot trail assessing apatinib combined with docetaxel(DTX)as second-line chemotherpy for RGFR negative advanced NSCLC[J]. J Thorac Oncol, 2018, 13(10): S497-S498.
25 Yu ZY. Potential challenge for second-line treatments of unresecta2le locally or advanced-stage non-small-cell lung carcinoma unharbored sensitive driver gene mutation: A pilot study of novel antiangiogenesis inhibitor(NCT: 0325672121)[J]. J Clin Oncol, 2018(suppl; abstr e21197).
26 Wu YP, Wu JJ, Tian SM, et al. Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC[J]. Medicine(Baltimore), 2019, 98(1): 1-6.
27 Yan X, Wang Q, Wang H, et al. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study[J]. J Cancer Res Clin Oncol, 2019, 145(1): 235-240.
28 Liu YT, Hu XS, Jiang J, et al. A prospective study of Apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy[J]. The Oncologist, Lung Cancer, 2020, 25(5): e833-842.
29 Fan Y, Huang Z, Li W, et al. A singel-arm multi-center phase Ⅱ study of apatinib in patients with ES-SCLC after second/third-line chemotherapy[J]. Presented at WCLC, 2018(P1.12).
30 Qin HF, Gao H. The efficacy of apatinib plus topotecan as laterline therapy for advenced small cell lung cencer. Presented at WCLC 2018(P2.12-06).
31 Hong W, Li H, Jin X, et al. Apatinib for chemotherapy-refractory extensive stage SCLC: results from a single-center retrospective study[J]. J Thorac Oncol, 2017, 12(1): S729.
32 Wang J, Fan Y, Zhao J, et al. Camrelizumab plus apatinib in extensive-stage small-cell lung cancer(PASSION): A multicenter, two-stage, phase 2 trial. AACR 2020, abstract CT083.
33 Fang S, Zhang M, Wei G, et al. Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR[J]. Oncotarget, 2018, 9: 7175-7181.
34 赵瑞华, 周亚楠, 李 鹤, 等. 阿帕替尼对晚期非小细胞肺癌患者的疗效及VEGFR2-906T>C多态性位点的影响[J]. 中华医学杂志, 2019, 99(2): 105-110.
35 Fang SC, Huang W, Zhang YM, et al. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib[J]. Onco Target Ther, 2019, 12: 985-992.

备注/Memo

备注/Memo:

基金项目: 国家重点研发计划(2018YFC1313600) 国家自然科学基金重点国际(地区)合作研究项目(81820108001) 国家自然科学基金项目(81670029) 连云港市卫生计生科技面上项目(201707)
通信作者: 周林福, Email: lfzhou@njmu.edu.cn

常用功能

更新日期/Last Update: 2020-08-20